Clinical data of 33 patients undergoing a reduced intensity allogeneic stem cell transplant Neg  0  No  3080  AW  830  55  CLL  1995  PB  CR  0  No  Colon  cancer   4202  AW   952  49  CLL  1996  PB  2  cGvHD  445  Dead  1041  57  CLL  1997  PB  2  cGvHD  2514  Dead  1119  46  MM  1998  BM  Yes  CR  Neg  0  No  2912  AW  970  55  NHL  1996  PB  0  Pneumonitis  706  Dead  899  54  CML  1996  PB  2  cGvHD  647  Dead  903  56  CML  1996  PB  CR  Neg  0  No  3837  AW  922  54  CML  1996  PB  2  cGvHD  418  Dead  926  50  CML  1996  PB  CR  Neg  0  No  3730  AW  936  59  CML  1996 With a median follow up for surviving patients of 10 years (8-11 years), 18 patients survive (Table 1) , with an actuarial survival of 55% (Figure 1) , a cumulative incidence of transplant-related mortality (TRM) of 18%, and a cumulative incidence of relapse-related death (RRD) of 27%. Survival was higher in patients with first CR/CP disease (64 vs 43%, P ¼ 0.1; Figure 2 ), due to a lower risk of RRD (17 vs 37%, P ¼ 0.2). All patients surviving have 100% donor chimerism.
Chronic GvHD developed in 54% of patients; was moderate in 42% and severe in 12%. It was seen in 75 vs 35% of patients receiving peripheral blood or marrow (P ¼ 0.02), and was the cause of death respectively in 25 vs 0% of patients. Causes of death were leukemia relapse, n ¼ 9, acute GvHD, n ¼ 1; chronic GvHD ¼ 4, pneumonitis ¼ 1 ( Table 1) . RRD were higher in BM transplant recipients as compared to PB transplants (35 vs 18%) whereas TRM was higher in PB grafts (6 vs 31%): survival was therefore similar 58% for BM and 51% for PB grafts (NS).
At the last follow up, 18 patients (55%) survived (Table 1) : 10 of the original 17 marrow recipients and 8 of 16 peripheral blood grafts recipients are alive. Four of six acute myeloid leukemia (AML) patients are alive in remission ( Table 1) ; 8 of 16 patients with CML are alive, 7 are in molecular remission and one patient is on tyrosine kinase inhibitors; of the 6 patients with lymphoproliferative diseases, two survive, one with multiple myeloma in remission with a negative rearrangement for VDJ and one chronic lymphocytic leukemia (CLL); one myelofibrosis has normal counts and no fibrosis; of 5 myelodysplastic (MDS) patients, 3 are alive in remission. Chronic GvHD at last follow up, in 17 patients, is either minimal (n ¼ 3) or absent (n ¼ 14) and all 17 are off immunosuppressive therapy. One patient (Table 1) developed extensive chronic GvHD after receiving donor lymphocyte infusions for relapsed MDS with deletion 7: he is now a full donor chimera, with normal cytogenetics and in hematologic remission, on immunosuppressive therapy. Two patients developed colon cancer, for which they have undergone colectomy and have currently no evidence of the original disease or of the secondary cancer.
In conclusion, this is an update of a previously published RIC regimen. We have shown long-term engraftment and survival in patients with hematologic malignancies, both for BM and PB graft recipients. With a median follow up of 10 years, transplant mortality remains low, especially in recipients of BM grafts. Chronic GvHD is seen more frequently in PB recipients, in keeping with other reports. Relapse-related death remains a problem, especially for patients beyond first CR/CP, and in patients receiving BM grafts. The quality of life is good in 16/18 surviving patients, with no chronic GvHD, no immunosuppressive therapy and no evidence of disease. One patient is alive in relapse, one patient has extensive chronic GvHD. Two patients have undergone surgery for colon cancer. Whether these results can further be improved remains to be determined. We believe it would be difficult to reduce transplant mortality below 15% at 10 years, in an elderly group of patients. Refinement of conditioning regimens, with increasing doses of thiotepa or by the addition of another alkylating agent such as busulfan or treosulfan may improve disease control. Letter to the Editor
